Novartis AG (VIE:NOVN)
Austria · Delayed Price · Currency is EUR | Market Cap | 250.85B +18.5% |
| Revenue (ttm) | 49.62B +2.7% |
| Net Income | 11.17B -6.6% |
| EPS | 5.79 -3.4% |
| Shares Out | n/a |
| PE Ratio | 22.46 |
| Forward PE | 16.59 |
| Dividend | 4.10 (3.07%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | n/a |
| Open | 133.94 |
| Previous Close | 133.08 |
| Day's Range | 133.14 - 133.94 |
| 52-Week Range | 103.18 - 143.52 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Novartis’ iptacopan granted FDA orphan designation
Novartis (NVS)’ iptacopan was granted FDA orphan designation as a treatment of atypical hemolytic uremic syndrome, according to a post to the agency’s website.
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent
Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug Entresto, with London's High Court rejecting a claim by Intas Pharmaceuticals' Accord Healthca...
Drugmakers curb Swiss reimbursement applications over US pricing concerns
Drugmakers are holding back applications for health insurance coverage in Switzerland over concerns that lower prices there could affect their U.S. business under drug-pricing policies introduced by ...
Novartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer
Novartis (NVS) announced the US Food and Drug Administration approved Pluvicto in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive ...
3 Dividend Stocks to Buy for a Lifetime of Passive Income
Novartis is expertly handling massive patent cliffs, which speaks volumes about how resilient its business is. Abbott Laboratories has attractive long-term opportunities within its core medical device...
Novartis price target raised to CHF 142 from CHF 132 at Citi
Citi analyst Graham Parry raised the firm’s price target on Novartis (NVS) to CHF 142 from CHF 132 and keeps a Buy rating on the shares.
Novartis CEO on 2Q Profit Beat, Investing in Pipeline
Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug...
Novartis Q2 Earnings Call Highlights
Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite con...
Novartis AG Earnings Call Transcript: Q2 2026
Q2 2026 saw 1% net sales growth and flat core operating income, driven by strong performance in key brands and launches, offsetting generic erosion. Full-year guidance is reaffirmed, with growth drivers showing robust momentum and multiple pivotal pipeline readouts expected in H2.
Novartis AG Quarterly report: Q2 2026
Novartis AG has published its Q2 2026 quarterly earnings report on July 21, 2026.
Novartis AG Slides: Q2 2026
Novartis AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.
Novartis AG Earnings release: Q2 2026
Novartis AG released its Q2 2026 earnings on July 21, 2026, summarizing the period's financial results.
Novartis CEO Vas Narasimhan says 'no change of plans'
Novartis chief executive officer Vas Narasimhan said on Tuesday he plans to stick around for the Swiss drugmaker's next phase of growth, ahead of a series of high-stakes trial data expected f...
Novartis reports Q2 core EPS $2.41 vs. $2.42 last year
Reports Q2 net sales $14.41B vs. $14.1B last year. Commenting on Q2 2026 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered a solid second quarter, returning to sales…
Novartis Q2 surpasses estimates despite 50% Entresto sales drop
Novartis beat market expectations for second-quarter core operating profit on Tuesday. Lower-than-expected costs helped the Swiss drugmaker offset a sharp decline in sales of its top-selling heart fai...
Novartis Returns to Growth on Sales Momentum From Key Drugs
Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.
Novartis Q2 profit up as generic competition mounts
Novartis' second-quarter core operating profit beat market expectations on Tuesday, helped by strong sales of cancer and multiple sclerosis drugs.
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum from Kisqali, Kesimpta, Scemblix and Pluvicto. We are encouraged by the early trajectory of our recent...
Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks?
While the first quarter showed weaker revenue and earnings, management had already warned that 2026 would begin with significant pressure from generic competition. The key question for traders and inv...
Novartis faces drug pipeline test with valuation premium in focus
Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss drugmake...
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growt...
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Novartis agrees to acquire Myricx Bio for up to $1.5B
Novartis (NVS) announced that it has entered into an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates, using N-myrist...
Novartis to Buy Myricx Bio for Up to $1.5 Billion
The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.
Novartis to acquire UK-based Myricx Bio for up to $1.5 billion
Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.